Friday

23rd Feb 2018

Opinion

Europe needs incentives to combat chronic disease

  • Chronic diseases are exacerbated by behaviour - smoking, alcohol consumption, lack of physical activity, and poor diet (Photo: Steve Baker)

This was a tumultuous year for the European Union, marked by continued economic malaise and the United Kingdom's historic decision to launch the process to leave.

Some are questioning whether the EU can survive the loss of its second-largest economy. Looking ahead to 2018, the inevitable belt-tightening will put public health budgets on the chopping block even as Europe faces a growing double-burden of aging and chronic disease.

As our leaders aim to get the EU back on track, they should remember that healthy populations are the basis for strong economic growth. Short-sighted policies that neglect public health and stifle future medical innovation will only deepen current problems.

The European Commission sounded fresh alarm on chronic diseases in The State of Health in the EU, published in conjunction with the OECD, the Paris-based club of wealthy nations, in October.

This biannual survey of European countries found that chronic diseases – cancer, diabetes, hypertension and others – comprise up to 80 percent of EU healthcare costs on average. The related deaths among working-age adults cost the continent €115 billion in lost productivity each year.

Because chronic diseases are exacerbated by behaviour - smoking, alcohol consumption, lack of physical activity, and poor diet - an ounce of prevention is truly worth a pound of cure.

More aggressive investment in deterring these behaviors would reduce treatment costs and boost economic productivity to the tune of billions of euros each year.

Yet, while politicians pay lip service to these grave concerns, EU member states spend on average only three percent of health budgets on prevention. Some measures have been adopted, such as the banning of online advertisements for alcohol.

Missing, however, are reasonable education programs to promote physical health and nutrition. Such measures require both political will and funding to properly implement them - both of which are in short supply in the current environment.

Equally important is avoiding short-sighted policies that seek quick fixes where none are needed. Chief among these is a persistent attack on protections and incentives for the discovery of new medicines.

The European Commission is only the latest institution to approach health care from this perspective. Based on the council conclusions of June 2016, the commission has been preparing an economic analysis of the impact of incentives on access to medicines, with the aim of proposing legislation in 2018.

The logic goes that by weakening incentives extended to biopharmaceutical companies for the discovery of new medicines to treat, for example, pediatric and rare diseases, governments might save a few dollars or somehow increase access to these medicines.

My many years as a practicing doctor and public official - including a term as Austria's health minister - have shown me that this is a sorely misguided effort.

Specific incentives for the research and development of pediatric treatments have spurred the discovery of 1,800 new medicines, providing families with more options in caring for children with debilitating conditions like juvenile arthritis.

Furthermore, establishing incentives for rare disease treatments in 2000 has led to a 16-fold increased in new medicines approved by the European Medicines Agency.

Diminishing these incentives won't put more treatments into the hands of people who need them most. But it will make it harder to produce these numbers going forward. With more than 7,000 new treatments in development - including hundreds targeting chronic diseases - this a big risk to take.

The EC review threatens to undermine such incentives at a time when we need more medical innovation - not less - to turn the tide against chronic diseases.

While I've personally felt the frustration of struggling to contain rising health care costs, the role of these incentives is part of a century of medical innovation that has yielded unprecedented gains in quality of life.

Look at what has been accomplished in just the past few decades.

European life expectancy has risen by six years since the 1990s. HIV has become a treatable illness. Hepatitis C is curable in 90 percent of cases. And more half of patients diagnosed with cancer live another five years.

These advances are unambiguously the product of incentives for medical innovation.

Any effort to undermine them will only deter inventors and investors at a time when the science of innovation is becoming riskier and more expensive.

While the specter of chronic diseases is daunting, there is a clear path to victory. European member states must invest more in prevention and avoid policies that deter vital investments in future treatments and cures.

I hope that when Austria assumes the oresidency of European Commission in July, it will keep a clear focus on public health and embrace these positions with vigor.

The future of the European Union may well depend on it.

Andrea Kdolsky was Austria's minister of health and family affairs from 2007 to 2008.

Interview

Health inequalities are economic issue, says commissioner

Social and geographical inequalities in Europeans' health are one of the main challenges for the EU, says health commissioner Vytenis Andriukaitis. He calls on finance ministers to look at the consequences for their country's economies and competitiveness.

Focus

EU calls for better disease prevention

EU health commissioner Vytenis Andriukaitis is encouraging states to spend more to prevent diseases that weigh much on health systems.

Greek government's steady steps to exit bailout programme

Growth predictions are positive, exports increasing, unemployment dropping and credit-ratings up, says the head of Greece's Syriza delegation to the European Parliament. Now the government in Athens is looking to design its own reform programme.

Analysis

We are not (yet) one people

Talks on the next EU budget will start on Friday. Brussels wants to do much more than before – and needs a lot more money. But arguing about funds won't be enough.

Intellectual property protection - the cure for Europe's ills

The European Commission is considering rolling back medical research incentives, on the faulty assumption they are somehow driving higher drug prices. But not only is that premise flawed – the proposed fix will do nothing to benefit ordinary health consumers.

News in Brief

  1. Report: EU to increase sanctions on Myanmar
  2. Juncker 'worried' by Italian elections
  3. EU migration to UK at lowest since 2012
  4. MEP Andrieu will chair parliament pesticide committee
  5. Juncker's right-hand man warns of 'institutional blockage'
  6. Greek parliament to open probe on PMs and EU commissioner
  7. May gathers Brexit ministers to hammer out UK position
  8. Tajani asks Juncker for all EMA Brexit relocation documents

Stakeholders' Highlights

  1. EPSUMovie Premiere: 'Up to The Last Drop' - 22 February, Brussels
  2. Aid & Trade LondonJoin Thousands of Stakeholders of the Global Aid Industry at Aid & Trade London
  3. Macedonian Human Rights Movement Int.European Free Alliance Joins MHRMI to End the Anti-Macedonian Name Negotiations
  4. Mission of China to the EUChina-EU Tourism Year to Promote Business and Mutual Ties
  5. European Jewish CongressAt “An End to Antisemitism!” Conference, Dr. Kantor Calls for Ambitious Solutions
  6. UNESDAA Year Ago UNESDA Members Pledged to Reduce Added Sugars in Soft Drinks by 10%
  7. International Partnership for Human RightsUzbekistan: Investigate Torture of Journalist
  8. CESICESI@Noon on ‘Digitalisation & Future of Work: Social Protection For All?’ - March 7
  9. UNICEFExecutive Director's Committment to Tackling Sexual Exploitation and Abuse of Children
  10. Nordic Council of MinistersState of the Nordic Region 2018: Facts, Figures and Rankings of the 74 Regions
  11. Mission of China to the EUDigital Economy Shaping China's Future, Over 30% of GDP
  12. Macedonian Human Rights Movement Int.Suing the Governments of Macedonia and Greece for Changing Macedonia's Name

Latest News

  1. EU leaders to kick off post-Brexit budget debate
  2. Greek government's steady steps to exit bailout programme
  3. Frontex: Europe's new law enforcement agency?
  4. Poland and Greece broke EU environment laws, rules court
  5. Dutch MPs vote on ending 'Ukraine-type' referendums
  6. Corruption report: Hungary gets worse, Italy makes progress
  7. UK seeks flexible transition length after Brexit
  8. Commission defence of Barroso meeting leaves 'discrepancies'

Stakeholders' Highlights

  1. Dialogue PlatformBeyond the Errors in the War on Terror: How to Fight Global Militarism - 22 February
  2. Swedish EnterprisesHarnessing Globalization- at What Cost? Keynote Speaker Commissioner Malmström
  3. European Friends of ArmeniaSave The Date 28/02: “Nagorno-Karabakh & the EU: 1988-2018”
  4. European Heart NetworkSmart CAP is Triple Win for Economy, Environment and Health
  5. European Free AlllianceEFA Joined the Protest in Aiacciu to Solicit a Dialogue After the Elections
  6. EPSUDrinking Water Directive Step Forward but Human Right to Water Not Recognized
  7. European Gaming & Betting AssociationGambling Operators File Data Protection Complaint Against Payment Block in Norway
  8. European Jewish CongressEJC Expresses Deep Concern Over Proposed Holocaust Law in Poland
  9. CECEConstruction Industry Gets Together to Discuss the Digital Revolution @ the EU Industry Days
  10. Mission of China to the EUChina-EU Relations in the New Era
  11. European Free AlllianceEnd Discrimination of European Minorities - Sign the Minority Safepack Initiative
  12. Centre Maurits Coppieters“Diversity Shouldn’t Be Only a Slogan” Lorant Vincze (Fuen) Warns European Commission